AbbVie Lowers 2026 EPS Guidance to $13.91-$14.11
AbbVie Inc. announced revised adjusted diluted EPS guidance of $13.91 to $14.11 for full-year 2026. The updated outlook incorporates a $291 million expense for acquired IPR&D and milestones, slightly lowering expectations from prior forecasts.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day